For triple-negative breast cancer, 52% of patients have low peripheral lymphocyte infiltration and poor PD-1/PD-L1 treatment [40], which is supported by the single-cell clustering results of the presented research, so targeting the relevant pathways and mechanisms may create a breakthrough. This evidence concerns the gene CD274 and triple-negative breast carcinoma.